CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Conmed Corp (CNMD) is not a strong buy at the moment for a beginner, long-term investor. While the company shows some positive financial growth in revenue and gross margin, the significant drop in net income and EPS, along with neutral trading sentiment and lack of strong technical or proprietary trading signals, suggests a hold position for now. The stock's overbought RSI and lack of clear positive catalysts further support this conclusion.
The MACD is positive but contracting, indicating a potential slowdown in momentum. RSI is at 80.867, signaling overbought conditions. Moving averages are converging, suggesting indecision in price direction. Key support is at 41.855, and resistance is at 46.454, with the stock currently trading near resistance levels.
Revenue growth of 7.88% YoY and gross margin improvement by 2.02% YoY in Q4 2025.
Analyst price target was lowered from $65 to $52 due to the exit from the gastroenterology product lines, which will be dilutive to earnings in
Overbought RSI and bearish options sentiment.
In Q4 2025, revenue increased by 7.88% YoY to $373.2M, gross margin improved to 58.49%, but net income dropped by 50.41% YoY to $16.7M, and EPS fell by 50% YoY to $0.54.
BofA has lowered the price target from $65 to $52 and maintains a Neutral rating, citing the impact of the company's exit from the gastroenterology product lines, which will improve gross margins but negatively affect earnings in 2026.
